CBFB and acute myeloid leukemia: In the United Kingdom (UK) studies MRC-AML10 and MRC-AML12, children with t(8;21)(q22;q22) (RUNX1::RUNX1T1) and inv(16)(p13q22) (CBFB::MYH11), the core-binding factor (CBF)-AML, had the best prognosis (80% OS rate), and the patients with chromosome 12 or 5q abnormalities, t(6;9)(p23;q34) (DEK::NUP214), monosomy 7, and t(9;22)(q34;q11) (BCR::ABL1) had the worst prognosis (36% OS rate) [23].